Impact of treatment with a Protein Tyrosine Kinase Inhibitor (Genistein) on acute and chronic experimental Schistosoma mansoni infection

Bibliographic Information
Authors: Sobhy M.M.K.; Mahmoud S.S.; El-Sayed S.H.; Rizk E.M.A.; Raafat A.; Negm M.S.I.
Journal: Experimental Parasitology
Publisher: Academic Press Inc.
Publication Date: February 2018
Volume / Issue: Volume 185
Pages: 115–123
ISSN: 144894
DOI: 10.1016/j.exppara.2018.01.013
Scopus: View on Scopus
PubMed: 29331278
Document Type: Article
Authors and Affiliations
Sobhy M.M.K., Medical Parasitology Department, Kasr Al-Ainy School of Medicine, Cairo University, Egypt; Mahmoud S.S., Theodor Bilharz Research Institute, Imbaba, Giza, Egypt; El-Sayed S.H., Theodor Bilharz Research Institute, Imbaba, Giza, Egypt, Medical Parasitology Department, Faculty of Medicine, Helwan University, Cairo, Egypt; Rizk E.M.A., Medical Parasitology Department, Kasr Al-Ainy School of Medicine, Cairo University, Egypt; Raafat A., Medical Parasitology Department, Kasr Al-Ainy School of Medicine, Cairo University, Egypt; Negm M.S.I., Pathology Department, Kasr Al-Ainy School of Medicine, Cairo University, Egypt
Abstract
Schistosomiasis mansoni is considered one of the most common fibrotic diseases resulting from inflammation and deposition of fibrous tissue around parasitic eggs trapped in the liver, causing morbidity and mortality. Chemotherapy against schistosomiasis is largely dependent on Praziquantel (PZQ). Yet, the huge administration of it in endemic areas and its incompetence towards the immature stages have raised serious alarms against the development of drug resistance. Few drugs are directed to reverse schistosomal liver fibrosis, particularly at the chronic and advanced stages of the disease. Recently, protein tyrosine kinase (PTK) inhibitors have been identified as potent anti-schistosomal and anti-fibrotic drugs against schistosomes, that may suppress and reverse Schistosoma mansoni (S. mansoni) induced liver fibrosis. The present study was designed to assess the anti-schistosomal and antifibrotic activity of Genistein, a PTK inhibitor, in comparison to PZQ, on both acute and chronic S. mansoni-infected mice using different parasitological, histopathological and immunohistochemical studies. Genistein showed a significant reduction (P <.05) in total worm burden, tissue egg load, mean hepatic granulomas diameter and numbers, percentage of collagen and expression of transforming growth factor-beta 1 (TGF-β 1) in the examined hepatocytes with elevation in percentage of degenerated ova, in comparison to the control groups, in both acute and chronic stages of infection. The best results were obtained when Genistein was combined with PZQ. Therefore, it was concluded that Genistein showed a promising anti-schistosomal and anti-fibrotic properties which could make it one of the new potential targets in chemotherapy against schistosomiasis. © 2018 Elsevier Inc.
Keywords
Antifibrotic; Collagen; Genistein; Praziquantel; Schistosoma mansoni; TGF-β 1; Acute Disease; Animals; Anthelmintics; Biomphalaria; Chronic Disease; Female; Granuloma; Image Processing, Computer-Assisted; Immunohistochemistry; Liver; Liver Cirrhosis; Male; Mice; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Schistosomiasis mansoni; transforming growth factor beta1; anthelmintic agent; protein kinase inhibitor; protein tyrosine kinase; animal cell; animal experiment; animal model; animal tissue; Article; controlled study; drug mechanism; experimental bacterial infection; histopathology; liver cell; liver granuloma; mouse; nonhuman; parasitology; priority journal; protein expression; Swiss Webster mouse; tumor number; tumor volume; worm burden; animal; antagonists and inhibitors; chemistry; drug effects; image processing; pathogenicity; pathology; veterinary
Citation Information
Scopus Citations: 31
For comprehensive information about the Theodor Bilharz Research Institute (TBRI), its institutional activities, scientific and research achievements, clinical and hospital services, and the diverse expertise offered through its 22 specialized research and clinical departments, as well as opportunities for professional training, specialized workshops, and scientific conferences, readers are invited to visit the Institute’s official website.
The website provides regularly updated information on the Institute’s latest news, research activities, scientific initiatives, clinical services, institutional programs, and academic and professional opportunities.
English Website: https://www.tbri.sci.eg/en/
Arabic Website: https://www.tbri.sci.eg/ar/
Prepared and Uploaded by:
Abdalla F. Abdalla
Electronic Portal Unit
